CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
We prospectively monitored 74 consecutive allogeneic and 50 autologous patients after bone marrow/stem cell transplantation from May 1999 to October 2000 at our institution with quantitative CMV PCR and pp65 antigen assay once weekly from conditioning therapy to days 120 and 80 after transplantation, respectively. Written informed consent was obtained from every patient. CMV prophylaxis consisted of acyclovir during transplant. Additionally all patients received only platelet products from CMV-negative donors. In the case of CMV infection preemptive therapy with gancyclovir was applied. In the case of CMV disease high-dose immunoglobulin was given as well. In the allogeneic setting 16 out of 74 (22%) patients developed a positive PCR. Seven episodes of a positive pp65 antigen assay occurred in six allograft recipients. In the autologous setting no positive assay was found during the whole observation period. Additionally, in 6/16 patients a lymphoproliferative assay was performed during CMV infection. Two patients showed a positive (15 and 5.4) and four a negative (2,1.6,1,1.8) stimulation index.
Schulenburg
A
A
Department of Medicine I, Bone Marrow Transplantation, University of Vienna, Vienna Austria.
Watkins-Riedel
T
T
Greinix
H T
HT
Rabitsch
W
W
Loidolt
H
H
Keil
F
F
Mitterbauer
M
M
Kalhs
P
P
D000293:Adolescent; D000328:Adult; D000956:Antigens, Viral / Q000097:blood*; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers; D016026:Bone Marrow Transplantation / Q000401:mortality; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D016867:Immunocompromised Host; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood*; D016133:Polymerase Chain Reaction / Q000379:methods*; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014763:Viral Matrix Proteins / Q000097:blood*; D014766:Viremia / Q000097:blood / Q000175:diagnosis* / Q000209:etiology
D000956:Antigens, Viral; D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir